2014
Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study
Bancroft E, Page E, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster C, Mitchell G, Drew K, Mæhle L, Axcrona K, Evans D, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeney L, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick P, Bojesen A, Skytte A, Lam J, Taylor L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams W, Oosterwijk J, Blanco I, Salinas M, Cook J, Rosario D, Buys S, Conner T, Ausems M, Ong K, Hoffman J, Domchek S, Powers J, Teixeira M, Maia S, Foulkes W, Taherian N, Ruijs M, Enden A, Izatt L, Davidson R, Adank M, Walker L, Schmutzler R, Tucker K, Kirk J, Hodgson S, Harris M, Douglas F, Lindeman G, Zgajnar J, Tischkowitz M, Clowes V, Susman R, Ramón y Cajal T, Patcher N, Gadea N, Spigelman A, van Os T, Liljegren A, Side L, Brewer C, Brady A, Donaldson A, Stefansdottir V, Friedman E, Chen-Shtoyerman R, Amor D, Copakova L, Barwell J, Giri V, Murthy V, Nicolai N, Teo S, Greenhalgh L, Strom S, Henderson A, McGrath J, Gallagher D, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Costello P, Eyfjord J, Rothwell J, Falconer A, Gronberg H, Hamdy F, Johannsson O, Khoo V, Kote-Jarai Z, Lubinski J, Axcrona U, Melia J, McKinley J, Mitra A, Moynihan C, Rennert G, Suri M, Wilson P, Killick E, Collaborators T, Moss S, Eeles R. Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. European Urology 2014, 66: 489-499. PMID: 24484606, PMCID: PMC4105321, DOI: 10.1016/j.eururo.2014.01.003.Peer-Reviewed Original ResearchConceptsPositive predictive valueHigh-risk diseaseBRCA2 mutation carriersProstate cancerTargeted prostate cancerMutation carriersBRCA1/2 mutationsHigh riskProstate-specific antigen (PSA) testingProstate cancer screeningScreening resultsGermline BRCA1/2 mutationsFisher's exact testInitial screening roundGermline genetic markersIdentification of tumorsBreast cancer 1Germline genetic risk variantsBreast cancer 2PCa incidencePSA levelsAntigen testingTumor characteristicsAggressive diseaseBRCA2 carriers
2013
Validation of association of genetic variants at 10q with prostate‐specific antigen (PSA) levels in men at high risk for prostate cancer
Chang B, Hughes L, Chen D, Gross L, Ruth K, Giri V. Validation of association of genetic variants at 10q with prostate‐specific antigen (PSA) levels in men at high risk for prostate cancer. BJU International 2013, 113: e150-e156. PMID: 23937305, PMCID: PMC3830710, DOI: 10.1111/bju.12264.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedGenetic VariationGenome-Wide Association StudyHumansMaleMiddle AgedProstate-Specific AntigenProstatic NeoplasmsRisk AssessmentWhite PeopleConceptsProstate Cancer Risk Assessment ProgramHigh-risk groupPSA levelsCaucasian manProstate cancerFamily historyProstate cancer screening strategiesProstate cancer screening studyCancer Risk Assessment ProgramBaseline PSA levelsTaqMan single nucleotide polymorphismCancer screening strategiesCancer screening studySingle nucleotide polymorphismsAfrican American ethnicityAllele carrier statusBRCA gene mutationsPotential confoundersAge 35Eligibility criteriaClinical relevanceT alleleRisk assessment programA alleleCarrier status
2012
Assessing the Clinical Role of Genetic Markers of Early-Onset Prostate Cancer among High-Risk Men Enrolled in Prostate Cancer Early Detection
Hughes L, Zhu F, Ross E, Gross L, Uzzo R, Chen D, Viterbo R, Rebbeck T, Giri V. Assessing the Clinical Role of Genetic Markers of Early-Onset Prostate Cancer among High-Risk Men Enrolled in Prostate Cancer Early Detection. Cancer Epidemiology Biomarkers & Prevention 2012, 21: 53-60. PMID: 22144497, PMCID: PMC3253936, DOI: 10.1158/1055-9965.epi-11-0727.Peer-Reviewed Original ResearchConceptsEarly-onset prostate cancerProstate cancer early detectionHigh-risk menCancer early detectionAfrican American menProstate cancerEarly detectionAmerican menConcordance indexClinical informationProstate cancer risk assessmentCancer diagnosisHarrell's concordance indexAfrican American raceFamilial prostate cancerUseful clinical informationCancer risk assessmentStudy criteriaLongitudinal cohortFamily historyAge 35Clinical roleCox modelEligibility criteriaAmerican race
2010
Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high‐risk men: effect of TMPRSS2 Met160Val
Giri V, Ruth K, Hughes L, Uzzo R, Chen D, Boorjian S, Viterbo R, Rebbeck T. Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high‐risk men: effect of TMPRSS2 Met160Val. BJU International 2010, 107: 466-470. PMID: 20735386, PMCID: PMC3052292, DOI: 10.1111/j.1464-410x.2010.09522.x.Peer-Reviewed Original ResearchConceptsHigh-risk menPCa diagnosisCaucasian manElevated prostate-specific antigen concentrationPCa screeningProstate Cancer Risk Assessment ProgramProstate-specific antigen concentrationCancer Risk Assessment ProgramProspective screening cohortCancer diagnosisProspective screening programCT/TTSecond-degree relativesAfrican American menTMPRSS2-ERG fusionUnderwent biopsyScreening cohortStudy entryAA menDegree relativesScreening programBRCA1/2 mutationsSelf-identified raceCox modelGene polymorphisms
2009
Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high‐risk screening population
Kaplan D, Boorjian S, Ruth K, Egleston B, Chen D, Viterbo R, Uzzo R, Buyyounouski M, Raysor S, Giri V. Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high‐risk screening population. BJU International 2009, 105: 334-337. PMID: 19709072, PMCID: PMC2809782, DOI: 10.1111/j.1464-410x.2009.08793.x.Peer-Reviewed Original ResearchConceptsProstate Cancer Risk Assessment ProgramProstate Cancer Prevention Trial Risk CalculatorProstate cancer riskHigh-risk menProstate cancerPSA levelsRisk scoreFamily historyAfrican American menPCPT calculatorRisk calculatorCancer riskLower baseline prostate-specific antigen levelsBaseline prostate-specific antigen levelLow baseline PSA levelsProstate-specific antigen levelCancer Risk Assessment ProgramBaseline PSA levelsMedian PSA levelRisk of diagnosisBaseline risk scoreMedian risk scoreProstate cancer ratesProstate cancer diagnosisPrevious biopsyRace, Genetic West African Ancestry, and Prostate Cancer Prediction by Prostate-Specific Antigen in Prospectively Screened High-Risk Men
Giri V, Egleston B, Ruth K, Uzzo R, Chen D, Buyyounouski M, Raysor S, Hooker S, Torres J, Ramike T, Mastalski K, Kim T, Kittles R. Race, Genetic West African Ancestry, and Prostate Cancer Prediction by Prostate-Specific Antigen in Prospectively Screened High-Risk Men. Cancer Prevention Research 2009, 2: 244-250. PMID: 19240249, PMCID: PMC2652509, DOI: 10.1158/1940-6207.capr-08-0150.Peer-Reviewed Original ResearchConceptsBaseline prostate-specific antigenProstate-specific antigenSelf-reported raceAfrican American menProstate cancerAmerican menProstate Cancer Risk Assessment ProgramCancer Risk Assessment ProgramEarly detectionProstate cancer early detectionHigh-risk cohortWest African ancestryAfrican American raceHigh-risk menLow PSA valuesProportional hazards modelRace-specific differencesProstate cancer predictionCancer early detectionEuropean American menAfrican ancestryHazard ratioPSA valuesFamily historyBRCA1/2 mutations
2008
Substantial family history of prostate cancer in black men recruited for prostate cancer screening
Mastalski K, Coups E, Ruth K, Raysor S, Giri V. Substantial family history of prostate cancer in black men recruited for prostate cancer screening. Cancer 2008, 113: 2559-2564. PMID: 18816608, PMCID: PMC2626163, DOI: 10.1002/cncr.23862.Peer-Reviewed Original ResearchConceptsFH of PCaProstate Cancer Risk Assessment ProgramNational Health Interview SurveyProstate cancerFamily historyBlack menCancer Risk Assessment ProgramMore first-degree relativesSelf-reported family historyMore family historyProstate cancer screeningHigh-risk menMen ages 35First-degree relativesHealth Interview SurveyAge-matched sampleSuboptimal screeningCancer screeningBreast cancerScreening programAge 35Colon cancerPCa screeningRisk assessment programCancer
2007
Prostate Cancer Risk Assessment Program: A 10-Year Update of Cancer Detection
Giri V, Beebe-Dimmer J, Buyyounouski M, Konski A, Feigenberg S, Uzzo R, Hanks G, Godwin A, Chen D, Gordon R, Cescon T, Raysor S, Watkins-Bruner D. Prostate Cancer Risk Assessment Program: A 10-Year Update of Cancer Detection. Journal Of Urology 2007, 178: 1920-1924. PMID: 17868726, DOI: 10.1016/j.juro.2007.07.010.Peer-Reviewed Original ResearchConceptsProstate Cancer Risk Assessment ProgramCancer Risk Assessment ProgramProstate-specific antigenProstate cancerSpecific antigenHigh riskRisk assessment programFamily historyNormal digital rectal examinationFree prostate-specific antigenLongitudinal screening programUnderwent prostate biopsyDigital rectal examinationProstate cancer incidenceGleason score 7Prostate cancer featuresGleason score 6Majority of cancersCancer detectionParticipants 19Biopsy criteriaLocal therapyRectal examinationProstate biopsyCancer incidence